Polaris Group, a privately held multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases in humans.

Polaris' lead project is ADI-PEG 20, a biotherapeutic agent that is in advanced clinical development for the treatment of hepatocellular carcinoma and metastatic melanoma.

Polaris is collaborating with EnzymeRx in the development of Uricase-PEG 20 for the treatment of gout, tumor lysis syndrome, and other diseases related to hyperuricemia.

Polaris is also researching and developing other biotherapeutic agents and has a small molecule drug program. The latter utilizes a rational structure-based approach for the design of novel compounds that inhibit the biological function of cancer-related protein targets.

Biotechnology

Pharmaceutical

Polaris Pharmaceuticals

Shaw T. Chen

Eric Van Rumund

Richard E. Showalter

Nien-Tsu Chen

The Research and Development Team at Polaris Pharmaceuticals focuses on the discovery and advancement of innovative biotherapeutic agents and small molecule drugs aimed at treating cancer and other severe diseases. This team is responsible for advancing lead projects like ADI-PEG 20, collaborating on initiatives such as Uricase-PEG 20 for hyperuricemia-related conditions, and pioneering new therapeutic compounds through structure-based design. They work collectively to bring these cutting-edge treatments from conceptual stages through clinical development.

Research and Development Team

About

Team members

Other teams at Polaris Pharmaceuticals

Leadership Team